Comparative semiology of drug-induced uveitis related to Checkpoint inhibitors and MAP-kinase pathway inhibitors

被引：0
|
作者：
Thibault, T. [1 ]
Dautriche, A. [2 ]
Auvens, C. [1 ]
Brunel, P. [3 ]
Boulay, C. [4 ]
Atzenhoffer, M. [5 ]
Devilliers, H. [1 ]
Grandvuillemin, A. [2 ]
机构：
[1] Univ Hosp Dijon Bourgogne, Internal Med & Syst Dis Unit, Dijon, France
[2] Univ Hosp Dijon Bourgogne, Reg Pharmacovigilance Ctr Burgundy, Dijon, France
[3] Univ Hosp St Etienne, Reg Pharmacovigilance Ctr, St Etienne, France
[4] Univ Hosp Rouen, Dept Pharmacol, Reg Pharmacovigilance Ctr, Rouen, France
[5] Hospices Civils Lyon, Dept Pharmacol & Toxicol, Reg Pharmacovigilance Ctr, Lyon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
checkpoint inhibitors; drug-induced uveitis; MAP-kinase pathway inhibitors;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
CO-056
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [21] RNA aptamers as pathway-specific MAP kinase inhibitors
    Seiwert, SD
    Nahreini, TS
    Aigner, S
    Ahn, NG
    Uhlenbeck, OC
    CHEMISTRY & BIOLOGY, 2000, 7 (11): : 833 - 843
  • [22] Drug therapy for myocarditis induced by immune checkpoint inhibitors
    Wu, Yihao
    Xu, Yizhou
    Xu, Linhao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [23] Therapeutical relevance of MAP-kinase inhibitors in renal diseases:: Current knowledge and future clinical perspectives
    Teresa Grande, M.
    Lopez-Novoa, Jose M.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (20) : 2054 - 2070
  • [24] Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
    Latham, Bethany D.
    Geffert, Raeanne M.
    Jackson, Klarissa D.
    DRUG METABOLISM AND DISPOSITION, 2024, 52 (06) : 479 - 492
  • [25] Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
    Eskiocak, Ugur
    Ramesh, Vijayashree
    Gill, Jennifer G.
    Zhao, Zhiyu
    Yuan, Stacy W.
    Wang, Meng
    Vandergriff, Travis
    Shackleton, Mark
    Quintana, Elsa
    Johnson, Timothy M.
    DeBerardinis, Ralph J.
    Morrison, Sean J.
    NATURE COMMUNICATIONS, 2016, 7
  • [26] Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
    Ugur Eskiocak
    Vijayashree Ramesh
    Jennifer G. Gill
    Zhiyu Zhao
    Stacy W. Yuan
    Meng Wang
    Travis Vandergriff
    Mark Shackleton
    Elsa Quintana
    Arthur E. Frankel
    Timothy M. Johnson
    Ralph J. DeBerardinis
    Sean J. Morrison
    Nature Communications, 7
  • [27] Drug-Induced Acute Coronary Syndrome: A New Cardiovascular Concern With Immune Checkpoint Inhibitors and the Need for a Prospective Registry
    Alhumaid, Waleed
    Paterson, D. Ian
    CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (04) : 455 - 456
  • [28] Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review
    Maloney, Nolan J.
    Rana, Jasmine
    Yang, Jason J.
    Zaba, Lisa C.
    Kwong, Bernice Y.
    SUPPORTIVE CARE IN CANCER, 2022, 30 (03) : 2839 - 2851
  • [29] Drug-induced physiologic changes and response to cancer therapies: Focus on immune checkpoint inhibitors and antibiotics in advanced melanoma
    Dyer, Mitchell
    Sheppard, Karen
    Mailer, Sonia
    Thai, Alesha
    Solomon, Ben
    Alexander, Marliese
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 169 - 169
  • [30] Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review
    Nolan J. Maloney
    Jasmine Rana
    Jason J. Yang
    Lisa C. Zaba
    Bernice Y. Kwong
    Supportive Care in Cancer, 2022, 30 : 2839 - 2851
12345